DreaMed Diabetes has gained FDA approval to expand its Advisor Pro Al Clinical Decision Support System expert-care platform for diabetes to patients with both type 1 and type 2 diabetes.
”There are simply not enough endocrinologists to provide the expert level care that all people with diabetes require continuously,” Eran Atlas, DreaMed’s Founder & CEO, said in a prepared statement. “In the U.S. alone, there are over 41,000 adults per endocrinologist which results in circa more than 50% of all people with diabetes that are not well managed due to limited access to proper care. DreaMed empowers the medical staff to treat significantly more patients by providing access to expert endocrinological advice in primary care settings. We can potentially help avoid thousands of unnecessary hospitalizations and medical complications for the community of people with diabetes and change the overall standards of care in this sector."
”Chronic diseases require constant care by experts," added Moshe Phillip, MD, DreaMed's chief science officer. "DreaMed has done significant clinical research to achieve a strong AI-based clinical decision support system that has just received the necessary FDA clearance."
Advisor Pro Al, which uses AI to optimize insulin administration, was previously cleared for patients with type 1 diabetes who utilize insulin pump therapy with continuous glucose sensors and/or blood glucose meters.